UAE Approves BioAro's Longevity+ Supplement, Signaling Major Market Potential in Global Preventive Health
bottle
Woman holding a longevity+ supplement bottle
Family photo
CALGARY, Alberta, July 08, 2025 (GLOBE NEWSWIRE) -- In a significant move that bridges biotechnology, preventive health, and global wellness trends, Canadian biotech company BioAro has announced the launch of its first nutraceutical product under its new supplement line: Longevity+™, a patent-pending, scientifically formulated capsule designed to support healthy aging through synergistic multi-molecule integration. With approvals already secured in the United Arab Emirates (UAE), BioAro is now poised for expansion into North America, Europe, the UK, and beyond.
The launch of Longevity+™ comes at a pivotal time, as the global longevity and healthy aging market is projected to surpass $44 billion by 2030, driven by growing demand for advanced nutraceuticals that go beyond basic supplementation. BioAro's entry into this space is far from ordinary. It brings together cutting-edge research, clinical insight, and multi-omics intelligence—hallmarks of its biotech origins—to deliver a product rooted in science, not hype.
A Breakthrough, All-in-One Longevity Protocol
What sets Longevity+™ apart is not just its formulation, but its philosophy: simplicity meets synergy. Each daily dose (two capsules) contains a potent blend of Nicotinamide Mononucleotide (NMN), Resveratrol, Coenzyme Q10, Curcumin, Vitamin D, and Vitamin B12—molecules that individually support cellular energy, mitochondrial health, inflammation modulation, and cognitive clarity. But when taken together in a precisely engineered ratio, early scientific research suggest they may create synergistic effects that amplify their individual benefits—potentially offering an integrated path to extending healthspan.
"We didn't want to be just another supplement company," says Dr. Anmol Kapoor, Founder of BioAro. "Our formulation was born from years of precision health research in genomics, metabolomics, and personalized medicine. We've built Longevity+ from a systems biology perspective, focusing on how molecules interact—not just how they function alone."
From Lab to Life: A Canadian Biotech's Global Ambition
Rooted in BioAro's legacy of precision diagnostics and AI-driven multi-omics, the supplement line represents the company's first consumer-facing health supplement product, translating years of complex research into a simple, daily protocol.
With regulatory clearance and market entry approval in the UAE, one of the world's most progressive markets for health and wellness innovation, BioAro is finalizing distribution partnerships across North America, Europe, the UK, India, and Southeast Asia. The company also plans to integrate Longevity+ into its clinical longevity programs, including personalized health assessments and digital wellness tracking, forming an end-to-end ecosystem for those seeking to proactively manage aging and vitality.
What's Inside Matters
NMN (Nicotinamide Mononucleotide): A powerful NAD+ precursor, vital for mitochondrial health and cellular repair.
Resveratrol: A polyphenol known to activate sirtuins and mimic caloric restriction benefits.
Coenzyme Q10: Essential for heart and energy metabolism, particularly in aging populations.
Curcumin: A potent anti-inflammatory and antioxidant compound from turmeric.
Vitamin D & B12: Crucial for immune modulation, neurocognitive health, and metabolic balance.
This formulation represents a shift toward systems-level thinking in supplementation—where the goal is not to overload the body with isolated nutrients, but to restore harmony at the molecular level.
Patent-Pending, Performance-Driven
Longevity+™ is currently under patent review for its novel combination and delivery mechanism, with BioAro leveraging its proprietary research in nutrient absorption optimization and bioavailability. Clinical pilot studies are in planning phases across Canada and the UAE, with an emphasis on biomarker tracking to validate outcomes in real-world populations.
Redefining the Future of Aging
With its entrance into the longevity supplement space, BioAro is not planning to just sell supplements, it is shaping a new narrative around aging, one where prevention and performance intersect, and where scientifically grounded strategies replace fragmented wellness advice.
"We envision a future where individuals manage aging proactively, backed by data, precision, and powerful science," adds Dr. Kapoor. "Longevity+ is just the beginning."
About BioAroBioAro Inc. is a Canadian biotechnology and precision health company focused on multi-omics, AI-driven diagnostics, and preventive medicine. With a presence across Canada, USA, GCC, South America, EU, and UK, BioAro is a pioneer in integrating genomics, wearable technology, and personalized therapeutics into everyday healthcare solutions.
Exclusive Offer!
As part of our commitment to advancing personalized wellness, BioAro is offering an exclusive discount on our premium longevity supplements for users who download the app Biongevity Playstore and Apple store or visit our website at www.biongevity.com. Start your journey to better health today!
For media inquiries, distribution partnerships, or product samples, contact:Media Contact:MohiniEmail: info@bioaro.comPhone: +1-403-250-2221
For more info, please visit: www.BioAro.com | www.biongevity.com
Longevity+™ is a trademark of BioAro Inc. Patent pending. These statements have not been evaluated by regulatory bodies in all jurisdictions. This product is not intended to diagnose, treat, cure, or prevent any disease.
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/b696ab44-9f1f-4fa0-89dc-e221bc2010d2
https://www.globenewswire.com/NewsRoom/AttachmentNg/ca4969a1-f8b7-404a-a505-674b3eb975a3
https://www.globenewswire.com/NewsRoom/AttachmentNg/86acd16a-ca50-48c9-b51c-237d91e36d51Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
1 dead, over 40 sick as legionnaires' outbreak spreads in southeast London, Ont.
One person is dead and more than 40 people have become ill in an outbreak of legionnaires' disease in London, Ont. The Middlesex-London Health Unit, which declared the outbreak, said the cases were reported within the last week. Most of the people with the severe respiratory illness live and/or work within a six-kilometre radius of one another, in the southeast side of the city, officials said. On Tuesday, officials said the health unit is working closely with Public Health Ontario and the Public Health Ontario Laboratories to investigate and try to determine the source of the outbreak, adding the investigation may take time as they need to do environmental samples of many types of cooling systems. "I know that is what most people are anxious to understand, is where it is coming from, and so are we. Unfortunately, we don't yet have a location," said Dr. Joanne Kearon, the health unit's associate medical officer of health. "Our teams go out to actually collect water samples and swabs from cooling systems and then send that to the lab to compare it to clinical samples from people who have become ill to see if we are able to find the source." The health unit has received 43 reports of Legionella this year, with a few cases reported each month, which Kearon said is expected. However, cases rose to more than 30 last week, prompting officials to declare the outbreak, she added. "Given the weather we've been having, it's understandable that it has spiked," she said. We compare it to what we would expect every season, and this exceeded significantly what we have seen previously." This is the second outbreak of legionnaires' disease in London since last summer. Last year's outbreak was localized in the city's east end and led to two deaths and 30 total reported infections. "At this time, it is not known whether it [the current outbreak] is the same location as the legionnella outbreak from last year," the health unit said. "However, this is being considered as part of the ongoing investigation." Bacteria found in water sources Legionnaires' disease is caused by legionella bacteria, naturally found in water sources such as hot tubs, cooling towers, hot water tanks, large plumbing systems or parts of air-conditioning systems. Legionella is not transmitted from person to person. If the bacteria are aerosolized or misted into the air (via wind or fans), people may inhale the bacteria and become unwell. Most people exposed to legionella don't get ill, but some may experience Pontiac fever, a mild, flu-like illness that commonly resolves itself. Individuals who are older, have lung problems or are immunocompromised (have a weak immune system) are at greater risk of serious infection. While she didn't have specific information about the individuals who contracted the illness, Kearon said there's a wide age range of people who've been affected, and those over 50 are at a higher risk. Health unit officials were not able to determine the exact source of the outbreak last year. The 2024 outbreak came to a natural end by late August as most cooling systems turn off around that time. The health unit predicts that will be the case this year as well. How outbreaks start Legionella bacteria can usually be found in faucets or HVAC units, but ultimately there needs to be an epidemiologic investigation to find the common source, according to Dr. Isaac Bogoch, an infectious disease specialist at Toronto General Hospital. He noted there can be sporadic cases from the soil, but most outbreaks are associated with contaminated water systems and buildings. The disease is not transmitted through human contact. "It's not in the air — it's in water — but you can usually pinpoint it to a common source," he said. "So for example, like an HVAC system in a particular building, you look for where all those people who are infected had a common source of contact." Health officials are able to detect the disease more easily as diagnostics have improved in recent years and more people are aware of it, but Bogoch said that doesn't necessarily mean legionnaires; disease is on the rise. Anyone who develops symptoms such as fever, cough and shortness of breath is encouraged to seek medical attention. All business owners and property managers should ensure all cooling equipment is regularly maintained and sanitized as per the manufacturer's instructions. Although masks can decrease the risk of infection, the health unit is not recommending regular community-wide use of them specifically for the prevention of legionnaire's disease, as the public risk is low.
Yahoo
3 hours ago
- Yahoo
Nuevocor Strengthens Board with Appointment of Thierry Abribat
SINGAPORE, July 7, 2025 /PRNewswire/ -- Nuevocor, a Singapore-headquartered biotechnology company developing cures for cardiomyopathies driven by aberrant mechanobiology, today announced the appointment of Dr. Thierry Abribat to its Board of Directors. Dr. Thierry Abribat is a seasoned biotech executive and serial entrepreneur with a proven track record of founding, leading, and successfully exiting three biotechnology companies, each focused on developing innovative therapies for patients with high unmet medical needs. He most recently orchestrated the $1 billion acquisition of Amolyt Pharma by AstraZeneca, underscoring his ability to scale and strategically position biotech companies for high-value exits. His other ventures include Alizé Pharma, acquired by Millendo Therapeutics in 2017 and Alizé Pharma 2, acquired by Jazz Pharmaceuticals in 2016. Dr. Abribat also held senior leadership roles in drug development, business development, and general management. He served as Chief Scientific Officer at Theratechnologies and as Chief Operating Officer at OPi SA, a specialty pharmaceutical company focused on rare diseases, which was acquired by EUSA Pharma in 2007. Dr. Abribat holds a Doctor of Veterinary Medicine degree and a PhD in neuroendocrinology from the National Polytechnic Institute of Toulouse. "I am excited to join Nuevocor at such a pivotal time in its journey toward becoming a clinical-stage company. Nuevocor's innovative mechanobiology-based approach has the potential to transform treatment for patients suffering from devastating genetic cardiomyopathies. I look forward to supporting the team as part of this Europe-Singapore partnership, as they advance this groundbreaking science into the clinic," said Dr. Thierry Abribat. "We are honored to welcome Dr. Thierry Abribat to Nuevocor's Board of Directors. Thierry is a highly accomplished biotech entrepreneur with a remarkable track record of building and scaling companies, and translating science into successful therapeutics. As we transition to a clinical-stage company and expand our presence in Europe, his strategic insights, deep operational expertise, and solution-oriented leadership will be invaluable. It's a privilege for us to work alongside him in advancing a potentially transformative therapy for patients suffering from debilitating cardiomyopathies," said Dr. Andreas Wallnöfer, Chairman of the Board. About NVC-001 NVC-001 is a first-in-class, AAV-based gene therapy for the treatment of LMNA-related dilated cardiomyopathy (LMNA DCM), one of the most aggressive forms of DCM with a rapid progression toward end-stage heart failure and malignant ventricular arrhythmias associated with increased risk of sudden cardiac death. NVC-001 is designed to reduce forces to the nucleus to restore nuclear envelope integrity, a hallmark of LMNA DCM, and treat disease. In preclinical studies, treatment with NVC-001 demonstrated significant benefits, including survival and cardiac function. Nuevocor plans to initiate a Phase 1/2 clinical trial in early 2026, with sites in the U.S. and Europe. About Nuevocor Nuevocor is biotechnology company developing novel therapies for genetic cardiomyopathies driven by aberrant mechanobiology, headquartered in Singapore with an office in the U.S. and expansion to Europe. Our unique approach, enabled by our proprietary PrOSIA mechanobiology platform, surpasses the limitations of traditional gene replacement therapy – which treats individual gene mutations – to treating defects in shared disease pathways across multiple cardiomyopathies by addressing the functional root cause of disease. Nuevocor is first-in-disease by addressing genetic cardiomyopathies that are not amendable to gene replacement therapy and have no effective treatment options. ( View original content to download multimedia: SOURCE Nuevocor Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
NativePath Launches Most Effective Activated Charcoal Yet—1,000mg Coconut-Shell Formula for Daily Gut Health
As consumer interest in the best activated charcoal grows, NativePath introduces a clean-label, high-purity formula derived from coconut shells to support bloating, gas, and digestive detox. Los Angeles, July 08, 2025 (GLOBE NEWSWIRE) -- NativePath, a clean-label wellness brand known for ingredient transparency and functional formulations, today announces the nationwide release of what may be its most effective activated charcoal product to date. Each serving delivers 1,000 mg of high-adsorption activated charcoal derived exclusively from raw coconut shells, selected for their microporous density and optimized surface area. Developed to support natural digestive detoxification and reduce occasional bloating and gas, the product reflects NativePath's commitment to clean-label sourcing, precision dosing, and third-party testing. As interest continues to rise in identifying the best activated charcoal supplement for daily gut health and toxin removal, NativePath Activated Charcoal offers a streamlined, high-purity option manufactured in a GMP-certified U.S. facility and third-party tested for potency, sourcing integrity, and consistency. Supporting Gut Health and Detox with Activated Charcoal Activated charcoal is a naturally porous compound known for its adsorption capacity—the ability to bind to unwanted materials in the digestive tract and support their elimination through natural pathways. Unlike absorption, which draws substances into a structure, adsorption allows toxins, gases, and metabolic byproducts to adhere to the surface of the charcoal for safe elimination via the gastrointestinal system. NativePath's formula features ultra-fine, pharmaceutical-grade charcoal activated at high temperatures in an oxygen-restricted environment. This process creates a dense network of micropores that increases surface area, allowing for greater binding of positively charged impurities commonly associated with digestive discomfort and internal toxin accumulation. The company's sourcing strategy relies on raw coconut shells, selected specifically for their microporous density, which has been shown to outperform other biomass sources in terms of structural uniformity and adsorption potential. Each capsule contains no synthetic fillers, binders, preservatives, or artificial ingredients, meeting the criteria for clean-label designation. Ingredient Science and Adsorption Mechanisms Scientific literature has long supported the physical adsorption properties of activated charcoal. Its molecular structure allows for electrostatic binding of charged particles, gases, and various toxins. When ingested, this structure functions much like a sponge, attracting and holding onto unwanted materials before being passed out of the body naturally. Unlike enzymatic detoxifiers, which require metabolic activation or liver filtration, charcoal's efficacy lies in its passive, non-systemic activity within the digestive tract. This makes it ideal for consumers seeking fast-acting bloating relief, digestive reset protocols, or natural gas relief supplements that do not rely on synthetic chemical reactions. NativePath's proprietary manufacturing process optimizes surface area and micropore availability, enhancing the ability of each 1,000 mg dose to bind with common dietary and environmental compounds—including preservatives, histamines, aldehydes, and other fermentation byproducts linked to gut discomfort. Ingredient Sourcing Comparison: Coconut Shell vs Other Forms A growing number of supplement users are now actively researching the differences between various charcoal sources. The three most common forms used in dietary supplements include coconut shell charcoal, hardwood charcoal, and bone charcoal. Coconut shell charcoal is regarded for its highest micropore density and exceptional surface area. It is ideal for premium detox applications and bloating relief due to its consistent structure and superior adsorption capacity. NativePath uses only this form in its formulation. Hardwood charcoal, while available in the supplement space, tends to offer moderate pore density and less structural consistency. It is often used in general detox applications but is not optimized for maximum adsorption. Bone charcoal, by contrast, presents variable pore size and may carry a higher risk of impurities. It is seldom used in dietary supplements and is more commonly applied in industrial filtration processes. Why Coconut Shell Wins: Its consistent micropore network provides superior surface area, enhancing its ability to adsorb gases and positively charged compounds. This makes coconut shell charcoal ideal for daily detox supplements, bloating support, and clean-label gastrointestinal health protocols. For more details on ingredient sourcing, dosage guidance, and third-party testing, visit the official NativePath Activated Charcoal product page at Trends Driving Demand for the Best Activated Charcoal Formulas According to trend analyses and consumer search behavior, activated charcoal has emerged as one of the most researched ingredients in the digestive health and detox supplement space. Keywords such as best activated charcoal for bloating, activated charcoal for gas and toxins, and charcoal supplement for detox have seen sustained growth, particularly among individuals aged 40 and older seeking non-pharmaceutical solutions to improve daily gut function. Search interest is especially high for phrases like what does activated charcoal do for gut health, how to use activated charcoal for detox, clean-label gas relief supplement, pharmaceutical-grade detox supplement, daily gut cleanse capsules, and natural bloating relief for adults. NativePath has positioned its product to align with these queries by offering a straightforward, research-aligned solution that prioritizes quality and ease of use. Many of these consumers are responding to environmental stressors such as air pollution, processed food consumption, chemical exposure, and internal toxic accumulation. Activated charcoal provides a mechanism by which these stressors can be addressed through physical binding rather than metabolic alteration, appealing to those interested in low-intervention wellness strategies. NativePath Activated Charcoal reflects these trends by offering a single-ingredient, clean-label product that requires no complex regimen to implement. Designed for use on an empty stomach—ideally 1 to 2 hours before or after food, medications, or supplements—the product supports routine digestive detoxification without interfering with other aspects of a consumer's lifestyle. Clean-Label Supplementation and Ingredient Integrity The rise in demand for clean-label supplements has prompted brands to remove artificial ingredients and focus on transparent sourcing and third-party testing. NativePath has built its identity around these priorities by formulating products with no additives, no artificial preservatives, and no genetically modified organisms. Each bottle of NativePath Activated Charcoal includes 30 servings, encapsulated in a neutral plant-based shell, allowing for efficient delivery and maximum purity. The formula's minimalist profile also makes it ideal for individuals with sensitivities to unnecessary excipients or proprietary blends. The company confirms that every production lot undergoes independent laboratory testing for contaminants, heavy metals, and potency levels, ensuring the product meets or exceeds U.S. supplement manufacturing standards. Consumer Applications: Bloating Relief, Gut Reset, and Environmental Detox Support NativePath Activated Charcoal serves a broad set of wellness scenarios relevant to today's health-conscious consumer. Among the most frequently cited use cases are: Bloating relief supplement after large meals or travel Daily support for internal gut cleansing without synthetic detox agents Short-term reset after alcohol, fast food, or processed food intake Environmental toxin exposure from water, plastics, and air pollutants Support during gastrointestinal irregularity or sluggish digestion By leveraging one of the most widely recognized physical detoxifiers, NativePath addresses the need for a reliable, clean, and easy-to-use activated charcoal formula that fits seamlessly into daily routines. Discover how NativePath's approach to digestive wellness and environmental toxin support aligns with the latest clean-label standards at Public Discourse and Consumer Awareness Conversations around digestive detox and bloating support have become increasingly mainstream in health-focused communities. Across wellness forums, nutrition podcasts, and social platforms, activated charcoal continues to receive attention for its role in supporting gut health through a simple, time-tested mechanism. While NativePath makes no medical claims and does not position its product as a cure or treatment, the formulation reflects key attributes that are consistently highlighted in public discussions: high dosage, coconut shell sourcing, clean-label compliance, and third-party testing. These characteristics support the decision-making process for consumers seeking clarity, transparency, and functionality in their supplement choices. Common Consumer Considerations on Activated Charcoal As consumer interest in activated charcoal grows, several common questions have emerged around safe usage, effectiveness, and best practices. The following points address widely searched topics in a neutral and informative manner to assist readers in making informed decisions based on available data and supplement labeling guidelines: Can activated charcoal be taken every day? NativePath Activated Charcoal is designed for regular use, provided it is taken away from medications and supplements to avoid unwanted interactions. Daily use should be guided by individual health needs and healthcare provider recommendations. Is activated charcoal effective for bloating and gas? Activated charcoal has a long history of use for binding intestinal gas and reducing discomfort related to occasional bloating. The 1,000 mg dosage in NativePath's formula aligns with common clinical protocols for digestive detox applications. What makes coconut shell charcoal preferable to other sources? Coconut shell is a preferred material due to its high micropore density, superior surface area, and sustainability profile. These characteristics enhance adsorption potential and are a primary reason for its use in NativePath's formulation. Can activated charcoal help with exposure to environmental toxins? While no supplement can eliminate all forms of toxin exposure, activated charcoal is frequently used to support the body's natural elimination process by binding positively charged compounds within the gastrointestinal tract. How should activated charcoal be timed around meals or supplements? It is typically recommended to take activated charcoal at least 1 to 2 hours before or after consuming food, supplements, or medications. This approach minimizes interference with nutrient absorption and optimizes its binding activity. These considerations reflect the types of questions being explored across public channels as interest in clean-label detox solutions and digestive health support continues to expand. Product Availability and Consumer Guidance NativePath Activated Charcoal is now available for direct purchase through the brand's official website: Product Details: Serving Size: 1,000 mg activated charcoal per capsule Count: 30 servings per bottle Type: Coconut-shell-derived, clean-label encapsulated formula Certifications: Non-GMO, third-party tested, GMP-certified production Usage Guidance: Take on an empty stomach at least 1–2 hours apart from food, medications, or supplements NativePath encourages consumers to consult with a healthcare provider prior to starting any new supplement, particularly if they are taking medications or managing chronic health concerns. About NativePath NativePath is a Miami-based wellness brand specializing in clean-label dietary supplements that align with traditional use and modern clinical insight. All products are formulated with transparency in mind and undergo third-party testing to confirm safety, purity, and potency. By using pharmaceutical-grade ingredients, sustainable sourcing, and strict quality protocols, NativePath delivers functional health solutions that empower consumers to support their wellness goals through accessible, evidence-informed tools. The company's focus on gut health, detox support, and age-related vitality continues to expand in alignment with growing public interest in simple, trustworthy supplements that meet today's standards for transparency, quality, and effectiveness. For more information, visit Disclaimer: The statements made in this release have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consumers are advised to consult with a qualified health professional before starting any new supplement regimen. Contact: NativePath Toll-Free: 1-800-819-2993 CONTACT: NativePath Toll-Free: 1-800-819-2993 in to access your portfolio
